Market Trends of Global Hyaluronidase Industry
This section covers the major market trends shaping the Hyaluronidase Market according to our research experts:
Animal Derived Hyaluronidase Segment is Expected to Witness Significant Growth Over the Forecast Period.
Most of the approved and sold brands of hyaluronidase come from animal sources. This is why animal-based hyaluronidase has a high market share. Bovine and porcine are some of the most widely used animal sources. Hydase (PrimaPharma), Vitrase (Bausch & Lomb Incorporated), and Amphadase (Amphastar Pharmaceuticals, Inc.) are some of the brands manufactured by manufacturers.
Also, there have been a lot of new products on the animal-derived hyaluronidase market, which has helped this segment grow.For example, in August 2021, Mesoestectic started selling a line of moisturizing solutions that contain hyaluronic acid to keep the skin hydrated.Thus, such developments are driving the growth of this segment.
Also, the fact that animal-based hyaluronidase is better than synthetic types is likely to help the studied segment grow. In the United States, more than 107,000 dermal filler surgeries are done each year, according to an article published by the NCBI in April 2021. So, a high number of dermal filler surgeries are likely to increase the need for hyaluronidase from animals, which will help this segment grow.
Therefore, the advantages of animal-based hyaluronidase and the fact that the majority of products contain animal-based hyaluronidase are driving this segment's growth.
North America is Expected to Witness Significant Growth Over the Forecast Period.
North America is expected to have a big share of the global hyaluronidase market because it has a lot of big companies that make these products, a lot of people who use advanced treatments, and a lot of dermatology clinics that prescribe these treatments. The fact that healthcare costs are rising and there is a well-established healthcare infrastructure is also very beneficial to the expansion of the regional market as a whole.
The study market is growing because more and more people are getting cosmetic surgery.For example, the Aesthetic Society said in January 2022 that in the United States, surgical procedures went up by 54% and non-surgical procedures went up by 44% in 2021. The source also said that in the United States in 2021, there would be 3,651,223 neurotoxin procedures, 1,857,339 dermal filler procedures, and 1,390,149 skin treatment procedures.So, the high number of non-surgical procedures done in the United States is increasing the demand for hyaluronidase and driving the growth of the studied market in the region.
In a similar vein, an article by Aesthetic Plastic Surgery from September 2021 claimed that mastopexy procedures were adaptable and increasing in popularity in Mexico.During the next few years, the increase in these kinds of procedures is likely to help the market grow.
Also in March 2022, Argenx SE, a global immunology company that works to improve the lives of people with severe autoimmune diseases, reported positive topline data from the Phase 3 ADAPT-SC study testing subcutaneous (SC) efgartigimod (1000 mg efgartigimod-PH20) as a treatment for generalized myasthenia gravis (gMG).Argenx submitted a biologics license application (BLA) to the USFDA. Thus, such applications of hyaluronidase in the treatment of various diseases are driving the growth of the market in the region.
As a result, the numerous applications for hyaluronidase and the prevalence of cosmetic procedures are driving the growth of the studied market in the area.
